Estamos no ar no ! Saiba mais

Liquidia Corp

LQDA

Valor de mercado US$ 3,07 bi

34,35 USD

-0,43

1,24%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

34,05

-0,30

0,87%

1 dia

-1,24%

5 dias

17,36%

1 mês

-49,82%

3 meses

-54,36%

6 meses

-17,03%

No acumulado do ano

9,39%

1 ano

48,19%

5 anos

875,85%

10 anos

209,46%

Sobre: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Funcionários: 216

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 50%

Neutro 41,7%

Negativo 8,3%

Zacks Investment Research

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Proactive Investors

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

24/7 Wall Street

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Investors Business Daily

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed

Liquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)

A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options

LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™